{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:56:05Z","timestamp":1788998165956,"version":"build-2803163510"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycystic ovarian syndrome (PCOS) is a multispectral disorder requiring lifelong management. Its pathophysiology is still being explored which makes its treatment options restrained. Present study explores impact of oral contraceptive mode of treatment on metabolic, hormonal, inflammation and coagulation profile of PCOS women. 50 subjects diagnosed with Rotterdam criteria receiving no drug treatment served as controls whereas 50 subjects receiving only OCPs (Ethinyl estradiol 0.03\u2009mg, Levonorgestrel 0.15\u2009mg) as a mode of treatment at least for six-months served as cases. Ferriman-Gallwey score and hormonal profile improved on OCP treatment. However, parameters like weight, Body mass index, waist-hip ratio, Oral glucose tolerance test, lipid profile, insulin, HOMA-IR, adiponectin, interleukin1\u03b2, visfatin, resistin, tissue factor, PT and APTT showed considerable derangements in OCP group. All above parameters are associated with the risk of diabetes mellitus, dyslipidemia, coronary vascular disease, cancers, hypercoagulable state, venous thromboembolism and thrombotic events. Long-term use of OCPs needs to be considered carefully for PCOS patients who are already burdened with associated risk factors. This study was conducted in a region where women do not have much access to high-end screening and diagnostic facilities that further exacerbates their clinical outcomes. Large scale, long-term studies need to be designed to further evaluate safety use of OCPs in PCOS women.<\/jats:p>","DOI":"10.1038\/s41598-019-46644-4","type":"journal-article","created":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T10:50:58Z","timestamp":1563187858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study"],"prefix":"10.1038","volume":"9","author":[{"given":"Saika","family":"Manzoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Ashraf","family":"Ganie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shajrul","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaffar A","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imtiyaz A","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Douhath","family":"Yousuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humira","family":"Jeelani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iram A","family":"Kawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qudsia","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzia","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,15]]},"reference":[{"key":"46644_CR1","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz, R. et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745\u20132749 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00404-008-0884-0","volume":"280","author":"L Kebapcilar","year":"2009","unstructured":"Kebapcilar, L., Taner, C. E., Kebapcilar, A. G. & Sari, I. High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch. Gynaecol. Obstet. 280, 187\u2013193 (2009).","journal-title":"Arch. Gynaecol. Obstet."},{"key":"46644_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CLEP.S37559","volume":"6","author":"SM Sirmans","year":"2013","unstructured":"Sirmans, S. M. & Pate, K. A. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 6, 1 (2013).","journal-title":"Clin Epidemiol."},{"key":"46644_CR4","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.amjmed.2014.04.017","volume":"127","author":"TL Setji","year":"2014","unstructured":"Setji, T. L. & Brown, A. J. Polycystic ovary syndrome: update on diagnosis and treatment. Am. J. Med. 127, 912\u2013919 (2014).","journal-title":"Am. J. Med."},{"key":"46644_CR5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/nri1937","volume":"6","author":"H Tilg","year":"2006","unstructured":"Tilg, H. & Moschen, A. R. Adipocytokines: Mediators Linking Adipose Tissue, Inflammation and Immunity. Nat. Rev. Immunol. 6, 772\u2013783 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"46644_CR6","first-page":"363","volume":"15","author":"I Copaci","year":"2006","unstructured":"Copaci, I., Micu, L. & Voiculescu, M. The role of cytokines in non-alcoholic steatohepatitis. A review. J. Gastrointestin. Liver Dis. 15, 363\u2013373 (2006).","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"46644_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","volume":"18","author":"V Braunersreuther","year":"2012","unstructured":"Braunersreuther, V., Viviani, G. L., Mach, F. & Montecucco, F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J.Gastroenterol. 18, 727\u2013735 (2012).","journal-title":"World J.Gastroenterol."},{"key":"46644_CR8","first-page":"255","volume":"77","author":"MO Goodarzi","year":"2002","unstructured":"Goodarzi, M. O. & Korenman, S. G. The importance of insulin resistance in polycystic ovary syndrome. Fertil. Steril. 77, 255\u2013258 (2002).","journal-title":"Fertil. Steril."},{"key":"46644_CR9","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1160\/TH13-01-0075","volume":"110","author":"PE Morange","year":"2013","unstructured":"Morange, P. E. & Alessi, M. C. Thrombosis in central obesity and metabolic syndrome: mechanisms and epidemiology. Thromb. Haemost. 110, 669\u2013680 (2013).","journal-title":"Thromb. Haemost."},{"key":"46644_CR10","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2337\/db05-1543","volume":"55","author":"ME Stegenga","year":"2006","unstructured":"Stegenga, M. E. et al. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 55, 1807\u20131812 (2006).","journal-title":"Diabetes."},{"key":"46644_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/1076029612436673","volume":"19","author":"G Frank","year":"2013","unstructured":"Frank, G., John, P. K., Neal, S. R. & Judi, M. Elevated Circulating Levels of Tissue Factor in Polycystic Ovary Syndrome. Clin. Appl. Thromb.\/Hemostasis. 19, 66\u201372 (2013).","journal-title":"Clin. Appl. Thromb.\/Hemostasis."},{"key":"46644_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/er.2003-0004","volume":"24","author":"RS Legro","year":"2003","unstructured":"Legro, R. S. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr. Rev. 24, 302\u2013312 (2003).","journal-title":"Endocr. Rev."},{"key":"46644_CR13","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1210\/jc.2004-1045","volume":"90","author":"T Apridonidze","year":"2005","unstructured":"Apridonidze, T., Essah, P. A., Iuorno, M. J. & Nestler, J. E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metabol. 90, 1929\u20131935 (2005).","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"46644_CR14","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/jc.2007-0282","volume":"92","author":"M Luque-Ram\u00c3rez","year":"2007","unstructured":"Luque-Ram\u00c3rez, M. et al. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 2453\u20132461 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR15","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1210\/jc.2003-032237","volume":"89","author":"EO Talbott","year":"2004","unstructured":"Talbott, E. O. et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J. Clin Endocrinol. Metab. 89, 5454\u20135461 (2004).","journal-title":"J. Clin Endocrinol. Metab."},{"key":"46644_CR16","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/jcem.87.8.8716","volume":"87","author":"BO Yildiz","year":"2002","unstructured":"Yildiz, B. O., Haznedaroglu, I. C., Kirazli, S. & Bayraktar, M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J. Clin. Endocrinol. Metab. 87, 3871\u20133875 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1161\/01.CIR.103.10.1410","volume":"103","author":"G Paradisi","year":"2001","unstructured":"Paradisi, G. et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 103, 410\u20131415 (2001).","journal-title":"Circulation."},{"key":"46644_CR18","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/aje\/152.10.897","volume":"152","author":"PA Sakkinen","year":"2000","unstructured":"Sakkinen, P. A., Wahl, P., Cushman, M., Lewis, M. R. & Tracy, R. P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol. 152, 897\u2013907 (2000).","journal-title":"Am. J. Epidemiol."},{"key":"46644_CR19","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1172\/JCI118709","volume":"97","author":"HO Steinberg","year":"1996","unstructured":"Steinberg, H. O. et al. Obesity\/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 97, 2601 (1996).","journal-title":"J. Clin. Invest."},{"key":"46644_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.tem.2007.07.003","volume":"18","author":"HcF Escobar-Morreale","year":"2007","unstructured":"Escobar-Morreale, H. C. F. & San Mill\u00e1n, J. L. Abdominal adiposity and the polycystic ovary syndrome. Trends. Endocrinol. Metab. 18, 266\u2013272 (2007).","journal-title":"Trends. Endocrinol. Metab."},{"key":"46644_CR21","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1001\/archinte.166.19.2081","volume":"166","author":"F Alvarez-Blasco","year":"2006","unstructured":"Alvarez-Blasco, F., Botella-Carretero, J., San Millan, J. & Escobar-Morreale, H. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch. Intern. Med. 166, 2081\u20132086 (2006).","journal-title":"Arch. Intern. Med."},{"key":"46644_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.fertnstert.2008.09.034","volume":"93","author":"HJ Teede","year":"2010","unstructured":"Teede, H. J. et al. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil and steril. 93, 184\u2013191 (2010).","journal-title":"Fertil and steril."},{"key":"46644_CR23","first-page":"1","volume":"9","author":"QS Akhter","year":"2014","unstructured":"Akhter, Q. S., Akhter, N., Begum, U. N. & Rahman, F. Assessment of Coagulation Disorder in Women Taking Oral Contraceptives. J Bangladesh Soc Physiol. 9, 1\u20135 (2014).","journal-title":"J Bangladesh Soc Physiol."},{"key":"46644_CR24","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1210\/jc.2004-2279","volume":"90","author":"E Carmina","year":"2005","unstructured":"Carmina, E. et al. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J. Clin. Endocrinol. Metab. 90, 2545\u20139 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2337\/diacare.24.1.89","volume":"24","author":"C Weyer","year":"2001","unstructured":"Weyer, C., Tataranni, P. A., Bogardus, C. & Pratley, R. E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 24, 89\u201394 (2001).","journal-title":"Diabetes Care."},{"key":"46644_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1210\/er.2005-0005","volume":"26","author":"T Kadowaki","year":"2005","unstructured":"Kadowaki, T. & Yamauchi, T. Adiponectin and adiponectin receptors. Endocr. Rev. 26, 439\u2013451 (2005).","journal-title":"Endocr. Rev."},{"key":"46644_CR27","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1007\/s00125-006-0419-9","volume":"49","author":"BK Tan","year":"2006","unstructured":"Tan, B. K. et al. Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome. Diabetologia 49, 2723\u20132728 (2006).","journal-title":"Diabetologia"},{"key":"46644_CR28","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/blood.V87.6.2095.bloodjournal8762095","volume":"87","author":"CA Dinarello","year":"1996","unstructured":"Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood. 87, 2095\u2013147 (1996).","journal-title":"Blood."},{"key":"46644_CR29","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1084\/jem.20030299","volume":"198","author":"T Matsuki","year":"2003","unstructured":"Matsuki, T., Horai, R., Sudo, K. & Iwakura, Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J. Exp. Med. 198, 877\u201388 (2003).","journal-title":"J. Exp. Med."},{"key":"46644_CR30","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1517\/14712590903136688","volume":"9","author":"K Maedler","year":"2009","unstructured":"Maedler, K., Dharmadhikari, G., Schumann, D. M. & St\u00f8rling, J. Interleukin-1 beta targeted therapy for type 2 diabetes. Expert. Opin. Biol. Ther. 9, 1177\u201388 (2009).","journal-title":"Expert. Opin. Biol. Ther."},{"key":"46644_CR31","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.bbrc.2009.11.066","volume":"391","author":"A Garten","year":"2010","unstructured":"Garten, A. et al. Nicotin amide phosphoribosyl transferase (NAMPT\/PBEF\/visfatin) is constitutively released from human hepatocytes. Biochem. Biophys. Res. Commun. 391, 376\u2013381 (2010).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"46644_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1126\/science.1097243","volume":"307","author":"A Fukuhara","year":"2005","unstructured":"Fukuhara, A. et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 307, 426\u201330 (2005).","journal-title":"Science."},{"key":"46644_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1126\/science.1106933","volume":"307","author":"C Hug","year":"2005","unstructured":"Hug, C. & Lodish, H. F. Medicine. Visfatin: a new adipokine. Science. 307, 366\u20137 (2005).","journal-title":"Science."},{"key":"46644_CR34","first-page":"e15503","volume":"12","author":"Fatemeh Farshchian.","year":"2014","unstructured":"Fatemeh Farshchian. et al. Visfatin and Resistin Serum Levels in Normal-Weight and Obese Women With Polycystic Ovary Syndrome. Int. J. Endocrinol. Metab. 12, e15503 (2014).","journal-title":"Int. J. Endocrinol. Metab."},{"key":"46644_CR35","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1128\/MCB.25.4.1569-1575.2005","volume":"25","author":"CM Steppan","year":"2005","unstructured":"Steppan, C. M., Wang, J., Whiteman, E. L., Birnbaum, M. J. & Lazar, M. A. Activation of SOCS-3 by resistin. Mol. Cell. Biol. 25, 1569\u20131575 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"46644_CR36","doi-asserted-by":"publisher","first-page":"34733","DOI":"10.1074\/jbc.M403886200","volume":"279","author":"H Shi","year":"2004","unstructured":"Shi, H., Tzameli, I., Bjorbaek, C. & Flier, J. S. Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling. J. Biol. Chem. 279, 34733\u201334740 (2004).","journal-title":"J. Biol. Chem."},{"key":"46644_CR37","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.2337\/db05-0615","volume":"55","author":"Y Qi","year":"2006","unstructured":"Qi, Y. et al. Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes. 55, 3083\u20133090 (2006).","journal-title":"Diabetes."},{"key":"46644_CR38","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/MEG.0b013e3282f16251","volume":"19","author":"A Konrad","year":"2007","unstructured":"Konrad, A. et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur. J. Gastroenterol. Hepatol. 19, 1070\u20131074 (2007).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"46644_CR39","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2478\/v10039-009-0035-2","volume":"54","author":"M Gnacinska","year":"2009","unstructured":"Gnacinska, M., Malgorzewicz, S., Stojek, M., Lysiak-Szydlowska, W. & Sworczak, K. Role of adipokines in complications related to obesity: a review. Adv. Med. Sci. 54, 150\u2013157 (2009).","journal-title":"Adv. Med. Sci."},{"key":"46644_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.abb.2005.06.005","volume":"440","author":"AJ Chu","year":"2005","unstructured":"Chu, A. J. Tissue factor mediates inflammation. Arch. Biochem. Biophysics. 440, 123\u2013132 (2005).","journal-title":"Arch. Biochem. Biophysics."},{"key":"46644_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1056-8727(00)00132-X","volume":"15","author":"ME Carr","year":"2001","unstructured":"Carr, M. E. Diabetes mellitus: a hypercoagulable state. J. Diabet. complications. 15, 44\u201354 (2001).","journal-title":"J. Diabet. complications."},{"key":"46644_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross, R. Atherosclerosis an inflammatory disease. N. Engl. J. Med. 340, 115\u2013126 (1999).","journal-title":"N. Engl. J. Med."},{"key":"46644_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MBC.0b013e3283365770","volume":"21","author":"A Mina","year":"2010","unstructured":"Mina, A., Favaloro, E. J., Mohammed, S. & Koutts, J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul. Fibrin. 21, 152\u2013157 (2010).","journal-title":"Blood Coagul. Fibrin."},{"key":"46644_CR44","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1182\/blood-2004-03-1042","volume":"104","author":"A Tripodi","year":"2004","unstructured":"Tripodi, A., Chantarangkul, V., Martinelli, I., Bucciarelli, P. & Mannucci, P. M. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood. 104, 3631\u20133634 (2004).","journal-title":"Blood."},{"key":"46644_CR45","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clinbiochem.2008.10.012","volume":"42","author":"G Lippi","year":"2009","unstructured":"Lippi, G. et al. Epidemiological association between fasting plasma glucose and shortened APTT. Clin. Biochem. 42, 118\u2013120 (2009).","journal-title":"Clin. Biochem."},{"key":"46644_CR46","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1210\/jcem.85.9.6779","volume":"85","author":"R Barazzoni","year":"2000","unstructured":"Barazzoni, R. et al. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J. Clin. Endocrinol. Metab. 85, 3121\u20133125 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1056\/NEJMcp033487","volume":"352","author":"WD James","year":"2005","unstructured":"James, W. D. Acne. N Engl J Med. 352, 1463\u20131472 (2005).","journal-title":"N Engl J Med."},{"key":"46644_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/humrep\/del407","volume":"22","author":"S Nader","year":"2007","unstructured":"Nader, S. & Diamanti-Kandarakis, E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum. Reprod. 22, 317\u201322 (2007).","journal-title":"Hum. Reprod."},{"key":"46644_CR49","first-page":"3327","volume":"80","author":"MT Korytkowski","year":"1995","unstructured":"Korytkowski, M. T. et al. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80, 3327\u201334 (1995).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR50","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1093\/humrep\/13.10.2706","volume":"13","author":"E Dahlgren","year":"1998","unstructured":"Dahlgren, E. et al. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod. 13, 2706\u201311 (1998).","journal-title":"Hum. Reprod."},{"key":"46644_CR51","first-page":"3074","volume":"82","author":"S Nader","year":"1997","unstructured":"Nader, S., Raid-Gabriel, M. G. & Saad, M. F. The effect of desogestrel-containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab. 82, 3074\u20133077 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR52","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/qjmed\/94.1.31","volume":"94","author":"VL Armstrong","year":"2001","unstructured":"Armstrong, V. L. et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyloestradiol\/cyproterone acetate. QJM. 94, 31\u20137 (2001).","journal-title":"QJM."},{"key":"46644_CR53","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/humrep\/15.4.785","volume":"15","author":"D Cibula","year":"2000","unstructured":"Cibula, D. et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum. Reprod. 15, 785\u20139 (2000).","journal-title":"Hum. Reprod."},{"key":"46644_CR54","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/humrep\/17.7.1729","volume":"17","author":"K Elter","year":"2002","unstructured":"Elter, K. et al. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum. Reprod. 17, 1729\u201337 (2002).","journal-title":"Hum. Reprod."},{"key":"46644_CR55","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2002-020997","volume":"88","author":"LC Morin-Papunen","year":"2003","unstructured":"Morin-Papunen, L. C. et al. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of non obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab. 88, 148\u2013156 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR56","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3109\/00016349209006227","volume":"71","author":"E Dahlgren","year":"1992","unstructured":"Dahlgren, E., Janson, P. O., Johansson, S., Lapidus, L. & Oden, A. Polycystic ovary syndrome and risk for myocardial infarction, evaluated from a risk factor model based on a prospective study of women. Acta. Obstet. Gynecol. Scand. 71, 599\u2013604 (1992b).","journal-title":"Acta. Obstet. Gynecol. Scand."},{"key":"46644_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1055\/s-2002-34785","volume":"34","author":"N Stefan","year":"2002","unstructured":"Stefan, N. & Stumvoll, M. Adiponectin\u2014its role in metabolism and beyond. Horm Metab Res. 34, 69\u2013474 (2002).","journal-title":"Horm Metab Res."},{"key":"46644_CR58","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1210\/jcem.87.6.8550","volume":"87","author":"M Matsubara","year":"2002","unstructured":"Matsubara, M., Maruoka, S. & Katayose, S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab. 87, 2764\u20132769 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"46644_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1365-2796.2004.01426.x","volume":"257","author":"ME Trujillo","year":"2005","unstructured":"Trujillo, M. E. & Scherer, P. E. Adiponectin-journey from an adipocytes secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257, 167\u201375 (2005).","journal-title":"J. Intern. Med."},{"key":"46644_CR60","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.2337\/diabetes.50.5.1126","volume":"50","author":"K Hotta","year":"2001","unstructured":"Hotta, K. et al. Circulating concentrations of the adipocytes protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 50, 1126\u201333 (2001).","journal-title":"Diabetes."},{"key":"46644_CR61","first-page":"519","volume":"27","author":"CA Dinarello","year":"2009","unstructured":"Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Acta. Obstet. Gynecol. Scand. 27, 519\u201350 (2009).","journal-title":"Acta. Obstet. Gynecol. Scand."},{"key":"46644_CR62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF02427283","volume":"29","author":"T Mandrup-Poulsen","year":"1998","unstructured":"Mandrup-Poulsen, T., Bendtzen, K. & Nerup, J. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia. 29, 63\u20137 (1998).","journal-title":"Diabetologia."},{"key":"46644_CR63","first-page":"2713","volume":"55","author":"DL Eizirik","year":"1988","unstructured":"Eizirik, D. L. Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is inhibitory protein-mediated \u03b2 -cell proliferation in human pancreatic islets. Diabetes. 55, 2713\u201322 (1988).","journal-title":"Diabetes."},{"key":"46644_CR64","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3346\/jkms.2007.22.1.117","volume":"22","author":"JH Kang","year":"2007","unstructured":"Kang, J. H., Yu, B. Y. & Youn, D. S. \u201cRelationship of serum adiponectin and resistin levels with breast cancer risk\u201d. J. Korean Med. Sci. 22, 117\u2013121 (2007).","journal-title":"J. Korean Med. Sci."},{"key":"46644_CR65","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.bbamcr.2008.01.004","volume":"1783","author":"SR Kim","year":"2008","unstructured":"Kim, S. R. et al. Visfatin enhances ICAM-1 and VCAM-1 expression through ROS-dependent NF-\u03baB activation in endothelial cells. Biochimet Biophys Acta (BBA)-Mol Cell Res. 1783, 886\u2013895 (2008).","journal-title":"Biochimet Biophys Acta (BBA)-Mol Cell Res."},{"key":"46644_CR66","doi-asserted-by":"crossref","unstructured":"Cymbaluk-P\u0142oska, A. et al. Circulating Serum Level of Visfatin in Patients with Endometrial Cancer. Bio Med res int (2018).","DOI":"10.1155\/2018\/8576179"},{"key":"46644_CR67","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/dmrr.1201","volume":"27","author":"YH Chang","year":"2011","unstructured":"Chang, Y. H., Chang, D. M., Lin, K. C., Shin, S. J. & Lee, Y. J. Visfatin in overweight\/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta\u2010analysis and systemic review. Diabetes Metab Res rev. 27, 515\u2013527 (2011).","journal-title":"Diabetes Metab Res rev."},{"key":"46644_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000111465","volume":"48","author":"AN Schuring","year":"2008","unstructured":"Schuring, A. N., Schulte, N., Sonntag, B. & Kiesel, L. Androgens and insulin two key players in polycystic ovary syndrome. Gynakol. Geburtshilfliche. Rundsch. 48, 9\u201315 (2008).","journal-title":"Gynakol. Geburtshilfliche. Rundsch."},{"key":"46644_CR69","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.thromres.2004.11.026","volume":"116","author":"F Carmassi","year":"2005","unstructured":"Carmassi, F. et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb. Res. 116, 207\u2013214 (2005).","journal-title":"Thromb. Res."},{"key":"46644_CR70","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jama.279.18.1477","volume":"279","author":"J Danesh","year":"1998","unstructured":"Danesh, J., Collins, R., Appleby, P. & Peto, R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. Jama. 279, 1477\u20131482 (1998).","journal-title":"Jama."},{"key":"46644_CR71","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.amjmed.2007.10.025","volume":"121","author":"NA Zakai","year":"2008","unstructured":"Zakai, N. A., Ohira, T., White, R., Folsom, A. R. & Cushman, M. Activated partial thromboplastin time and risk of future venous thromboembolism. Am. J. Med. 121, 231\u2013238 (2008).","journal-title":"Am. J. Med."},{"key":"46644_CR72","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/bjc.1995.260","volume":"71","author":"MP Vessey","year":"1995","unstructured":"Vessey, M. P. & Painter, R. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study. British J cancer. 71, 1340 (1995).","journal-title":"British J cancer."},{"key":"46644_CR73","first-page":"552","volume-title":"Lancet Oncol.","author":"V Cogliano","year":"2005","unstructured":"Cogliano, V. et al. For the WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 6, 552\u201353 (2005)."},{"key":"46644_CR74","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(03)12949-2","volume":"361","author":"JS Smith","year":"2003","unstructured":"Smith, J. S. et al. Cervical cancer and use of hormonal contraceptives: a systematic review. The Lancet. 361, 1159\u20131167 (2003).","journal-title":"The Lancet."},{"key":"46644_CR75","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and \u00ce\u00b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetolgia. 28, 412\u2013419 (1985).","journal-title":"Diabetolgia."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46644-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46644-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T11:32:47Z","timestamp":1671276767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-46644-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,15]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["46644"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-46644-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,15]]},"assertion":[{"value":"3 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10182"}}